Eyevance Pharmaceuticals has appointed Julie Speed to the position of Chief Commercial Officer. In her new role, Ms. Speed will be responsible for developing the commercial strategy and overseeing the growth of Eyevance’s product portfolio, including Flarex (fluorometholone acetate) 0.1%, Freshkote Preservative Free Tear Lubricant, the upcoming launch of Zerviate (cetirizine ophthalmic solution) 0.24% and the recently-acquired Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and Natacyn (natamycin ophthalmic suspension) 5%. Ms. Speed will join the Eyevance Executive Leadership team and report directly to the CEO of Eyevance.
Ms. Speed brings over 21 years of proven ophthalmic experience to Eyevance, including deep expertise in the ocular surface and anterior segment subspecialties. Most recently, Ms. Speed served as Senior Director, US Marketing at Johnson & Johnson Vision, where she led the organization’s cataract and refractive surgical business within the United States. Prior to her tenure at Johnson & Johnson Vision, Ms. Speed served as Vice President of Global Marketing at TearLab Corporation, where she built an accomplished marketing team from the ground up and successfully realigned the organization’s global marketing strategy. In addition, Ms. Speed spent over 15 years at Alcon in various, progressing commercial management positions.
“It’s an honor to join the Eyevance team at this crucial stage in the Company’s emerging growth phase,” Ms. Speed said in company news release. “Eyevance’s robust product pipeline of commercial and development stage assets have the opportunity to address many unmet ophthalmic market needs, which will position the organization for sustained success in 2020 and beyond. I look forward to putting my experience, knowledge, and passion to work for the Eyevance team, and to engaging key opinion leaders within ophthalmology and optometry in this new and exciting role.”